Next-Gen Cell Line Characterization For Safer, Faster Drug Development

By Valentina Armiento, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

Ensuring the integrity of cell lines is fundamental to producing safe, effective biopharmaceuticals. As therapies become more advanced, developers face increasing pressure to confirm identity, genetic stability, and purity with speed and accuracy. Next-generation sequencing (NGS) is reshaping this landscape by providing deeper insights than traditional assays and enabling a more complete view of cell line quality in a single workflow. Modern approaches now support everything from clone selection and contamination detection to long-term cell bank monitoring, aligning with global regulatory expectations from ICH, WHO, EMA, and FDA.

Explore how comprehensive genetic analysis, streamlined bioinformatics, and emerging AI-driven tools are accelerating development timelines while strengthening quality control. Access the full article to explore detailed workflows, regulatory context, and real-world applications.